Aastrom Biosciences, Inc. (ASTM) to Present at the ROTH Capital Partners 24th Annual Conference

Aastrom Biosciences is a biotech company engaged in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company’s clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and its DCM development program, which is in phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. phase II trials to investigate surgical and catheter-based delivery for its product in the treatment of DCM. For more information visit the company’s Web site at www.aastrom.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html